A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

NCT02402062

Last updated date
Study Location
Institut Catalá d'Oncologia L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neuroendocrine Tumors, Pancreatic Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female, 18 years of age or older.

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

- Histologically proven diagnosis of pancreatic neuroendocrine tumors (pNET) with Ki67 assessment of ≤ 20% (well and moderately differentiated)

- Evidence of unresectable disease or metastatic disease. Locally advanced disease must not be amendable to resection or radiation therapy with curative intent.

- Patients may be treated with somatostatin analogues prior or during the trial. Concomitant or prior interferon treatment is not permitted.

- Documented progression disease by CT scan, magnetic resonance (MR) or Octreoscan in 12 months prior basal visit.

- Measurable disease as per RECIST. Measurable lesions that have been previously radiated will not be considered target lesions unless increase in size has been observed following completion of radiation therapy.

- Patient has to be able to swallow the medication.

- Life expectancy greater than 12 weeks.

- The definitions of minimum adequacy for organ function required prior to study entry are as follows:

- Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN), or AST and ALT ≤ 5 x ULN if liver function abnormalities are due to underlying malignancy

- Total serum bilirubin ≤ 1.5 x ULN

- Serum albumin ≥ 3.0 g/dL

- Absolute neutrophil count (ANC) ≥ 1500/µL

- Platelets ≥ 100,000/µL

- Hemoglobin ≥ 5,6 mmol/L (9.0 g/dL)

- Creatinin clearance > 40 mL/min (Cockcroft and Gault formula)

- Adequate cardiac function: 12-lead ECG without pathologic findings (clinically significant alterations are allowed) and Echocardiogram / Normal multiple gated acquisition scan (MUGA) (LVEF> 50%)

- Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.

- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Previous treatments with chemotherapy, monoclonal antibodies anti-vascular endothelial
growth factor (VEGF), tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR)
inhibitors, or interferon are not permitted for the advanced disease.


- Prior treatment on another hypoxia-activated prodrug under clinical trial.


- Major surgery, radiation therapy, or systemic therapy within 3 weeks of study
randomization except palliative radiotherapy to non-target metastatic lesions.


- Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.


- Immunosuppressive drugs such as cyclosporine, tacrolimus, azathioprine, or long-term
oral glucocorticoids taken concurrently or within last 3 months prior to randomization


- Treatment with known inhibitors or inductors of cytochrome P450 3A4 (CYP3A4) or that
prolong the QT interval in the previous 7 days.


- Prior radiation therapy to > 25% of the bone marrow.


- Current treatment on another clinical trial.


- Uncontrolled brain metastases, spinal cord compression, carcinomatous meningitis, or
leptomeningeal disease. Patients should have completed surgery or radiation therapy
for existing brain metastases, should not have documented increase in size over the
previous 3 months prior to first dose of treatment on study and should be
asymptomatic.


- Diagnosis of any second malignancy within the last 3 years, except for adequately
treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.


- Any of the following within the 12 months prior to starting study treatment:


- myocardial infarction,


- severe/unstable angina,


- coronary/peripheral artery bypass graft,


- congestive heart failure class III or IV of the New York Heart Association (NYHA)
or patients with clinical history of congestive heart failure class III or IV of
the NYHA, unless an echocardiogram or MUGA in the previous 3 months to selection
shows a LVEF ? 45 %


- significant heart valve disease


- cerebrovascular accident including transient ischemic attack


- pulmonary embolus.


- Ongoing cardiac dysrhythmias of NCI Common Toxicity Criteria for Adverse Effects
(CTCAE) grade ≥ 2, atrial fibrillation of any grade, or corrected QT interval (QTc)
interval >450 msec for males or >470 msec for females.


- Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal
medical therapy)


- Chronic obstructive pulmonary disease (COPD) or any other disease concurrent with
hypoxemia or oxygen saturation < 90% after a march of two minutes.


- Current treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg PO
daily for deep vein thrombosis prophylaxis is allowed).


- Known human immunodeficiency virus infection.


- Pregnancy or breastfeeding. All female patients with reproductive potential must have
a negative pregnancy test (serum or urine) prior to inclusion.


- Previous allergic reaction to components structurally similar to TH-302 or sunitinib
or any of the excipients of drugs.


- Non-healing wound, fistulae, active peptic ulcer or bone fracture.


- Other severe acute or chronic medical or psychiatric condition, or laboratory
abnormality that would impart, in the judgment of the investigator, excess risk
associated with study participation or study drug administration, or which, in the
judgment of the investigator, would make the patient inappropriate for entry into this
study.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Neuroendocrine Tumors, Pancreatic NeoplasmsA Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
NCT02402062
  1. L'Hospitalet de Llobregat, Barcelona
  2. Santander, Cantabria
  3. Castelló, Valencia
  4. Barcelona,
  5. Granada,
  6. Madrid,
  7. Madrid,
  8. Madrid,
  9. Málaga,
  10. Sevilla,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Official Title  ICMJE A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)
Brief Summary The purpose of this study is to determine the safety and the efficacy of the combination of the drugs TH-302 and sunitinib in metastatic neuroendocrine tumours.
Detailed Description The purpose of this study is to determine the safety and the efficacy of the combination of the drugs TH-302 and sunitinib in Treatment-naïve patients with well- and moderately-differentiated metastatic Pancreatic Neuroendocrine Tumours (pNET).
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Neuroendocrine Tumors
  • Pancreatic Neoplasms
Intervention  ICMJE Drug: TH-302 + Sunitinib

Combination of the two drugs in cycles of 28 days, described as follows:

Sunitinib: 37,5 mg/day Oral everyday of each 28 day cycle.

TH-302: 340 mg/m2 IV on days 8, 15 and 22 of each cycle.

Other Name: TH-302 + Sutent
Study Arms  ICMJE Experimental: TH-302 + Sunitinib
TH-302 + Sunitinib. Single arm Study.
Intervention: Drug: TH-302 + Sunitinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 9, 2020)
17
Original Estimated Enrollment  ICMJE
 (submitted: March 24, 2015)
43
Actual Study Completion Date  ICMJE January 10, 2020
Actual Primary Completion Date May 31, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female, 18 years of age or older.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  • Histologically proven diagnosis of pancreatic neuroendocrine tumors (pNET) with Ki67 assessment of ? 20% (well and moderately differentiated)
  • Evidence of unresectable disease or metastatic disease. Locally advanced disease must not be amendable to resection or radiation therapy with curative intent.
  • Patients may be treated with somatostatin analogues prior or during the trial. Concomitant or prior interferon treatment is not permitted.
  • Documented progression disease by CT scan, magnetic resonance (MR) or Octreoscan in 12 months prior basal visit.
  • Measurable disease as per RECIST. Measurable lesions that have been previously radiated will not be considered target lesions unless increase in size has been observed following completion of radiation therapy.
  • Patient has to be able to swallow the medication.
  • Life expectancy greater than 12 weeks.
  • The definitions of minimum adequacy for organ function required prior to study entry are as follows:

    • Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ? 2.5 x upper limit of normal (ULN), or AST and ALT ? 5 x ULN if liver function abnormalities are due to underlying malignancy
    • Total serum bilirubin ? 1.5 x ULN
    • Serum albumin ? 3.0 g/dL
    • Absolute neutrophil count (ANC) ? 1500/µL
    • Platelets ? 100,000/µL
    • Hemoglobin ? 5,6 mmol/L (9.0 g/dL)
    • Creatinin clearance > 40 mL/min (Cockcroft and Gault formula)
  • Adequate cardiac function: 12-lead ECG without pathologic findings (clinically significant alterations are allowed) and Echocardiogram / Normal multiple gated acquisition scan (MUGA) (LVEF> 50%)
  • Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria:

  • Previous treatments with chemotherapy, monoclonal antibodies anti-vascular endothelial growth factor (VEGF), tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR) inhibitors, or interferon are not permitted for the advanced disease.
  • Prior treatment on another hypoxia-activated prodrug under clinical trial.
  • Major surgery, radiation therapy, or systemic therapy within 3 weeks of study randomization except palliative radiotherapy to non-target metastatic lesions.
  • Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.
  • Immunosuppressive drugs such as cyclosporine, tacrolimus, azathioprine, or long-term oral glucocorticoids taken concurrently or within last 3 months prior to randomization
  • Treatment with known inhibitors or inductors of cytochrome P450 3A4 (CYP3A4) or that prolong the QT interval in the previous 7 days.
  • Prior radiation therapy to > 25% of the bone marrow.
  • Current treatment on another clinical trial.
  • Uncontrolled brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease. Patients should have completed surgery or radiation therapy for existing brain metastases, should not have documented increase in size over the previous 3 months prior to first dose of treatment on study and should be asymptomatic.
  • Diagnosis of any second malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
  • Any of the following within the 12 months prior to starting study treatment:

    • myocardial infarction,
    • severe/unstable angina,
    • coronary/peripheral artery bypass graft,
    • congestive heart failure class III or IV of the New York Heart Association (NYHA) or patients with clinical history of congestive heart failure class III or IV of the NYHA, unless an echocardiogram or MUGA in the previous 3 months to selection shows a LVEF ? 45 %
    • significant heart valve disease
    • cerebrovascular accident including transient ischemic attack
    • pulmonary embolus.
  • Ongoing cardiac dysrhythmias of NCI Common Toxicity Criteria for Adverse Effects (CTCAE) grade ? 2, atrial fibrillation of any grade, or corrected QT interval (QTc) interval >450 msec for males or >470 msec for females.
  • Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy)
  • Chronic obstructive pulmonary disease (COPD) or any other disease concurrent with hypoxemia or oxygen saturation < 90% after a march of two minutes.
  • Current treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).
  • Known human immunodeficiency virus infection.
  • Pregnancy or breastfeeding. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to inclusion.
  • Previous allergic reaction to components structurally similar to TH-302 or sunitinib or any of the excipients of drugs.
  • Non-healing wound, fistulae, active peptic ulcer or bone fracture.
  • Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02402062
Other Study ID Numbers  ICMJE GETNE-1408
2014-004072-30 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Grupo Espanol de Tumores Neuroendocrinos
Study Sponsor  ICMJE Grupo Espanol de Tumores Neuroendocrinos
Collaborators  ICMJE
  • Threshold Pharmaceuticals
  • Pfizer
Investigators  ICMJE
Study Chair:Enrique Grande, MDGrupo Espanol de Tumores Neuroendocrinos
PRS Account Grupo Espanol de Tumores Neuroendocrinos
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP